0001183740-24-000036.txt : 20240410 0001183740-24-000036.hdr.sgml : 20240410 20240410150427 ACCESSION NUMBER: 0001183740-24-000036 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20240410 DATE AS OF CHANGE: 20240410 EFFECTIVENESS DATE: 20240410 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Algernon Pharmaceuticals Inc. CENTRAL INDEX KEY: 0001642178 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: A1 FISCAL YEAR END: 0831 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-510248 FILM NUMBER: 24835497 BUSINESS ADDRESS: STREET 1: 400 - 601 WEST BROADWAY CITY: VANCOUVER STATE: A1 ZIP: V5Z 4C2 BUSINESS PHONE: 6043984175 MAIL ADDRESS: STREET 1: 400 - 601 WEST BROADWAY CITY: VANCOUVER STATE: A1 ZIP: V5Z 4C2 FORMER COMPANY: FORMER CONFORMED NAME: Breathtec BioMedical, Inc. DATE OF NAME CHANGE: 20161207 FORMER COMPANY: FORMER CONFORMED NAME: Breathtec Biomedical, Inc. DATE OF NAME CHANGE: 20150512 D 1 primary_doc.xml X0708 D LIVE 0001642178 Algernon Pharmaceuticals Inc. 400 - 601 WEST BROADWAY VANCOUVER A1 BRITISH COLUMBIA, CANADA V5Z 4C2 6043984175 BRITISH COLUMBIA, CANADA Breathtec BioMedical, Inc. Breathtec Biomedical, Inc. Corporation true Christopher Moreau 400 - 601 West Broadway Vancouver A1 BRITISH COLUMBIA, CANADA V5Z 4C2 Executive Officer Director Chief Executive Officer James Kinley 400 - 601 West Broadway Vancouver A1 BRITISH COLUMBIA, CANADA V5Z 4C2 Executive Officer Chief Financial Officer Christopher Bryan 400 - 601 West Broadway Vancouver A1 BRITISH COLUMBIA, CANADA V5Z 4C2 Executive Officer VP, Research & Operations Harry Bloomfield 400 - 601 West Broadway Vancouver A1 BRITISH COLUMBIA, CANADA V5Z 4C2 Director Raj Attariwala 400 - 601 West Broadway Vancouver A1 BRITISH COLUMBIA, CANADA V5Z 4C2 Director Howard Gutman 400 - 601 West Broadway Vancouver A1 BRITISH COLUMBIA, CANADA V5Z 4C2 Director Mark Williams 400 - 601 West Broadway Vancouver A1 BRITISH COLUMBIA, CANADA V5Z 4C2 Director Biotechnology Decline to Disclose 06b false 2024-04-03 false true false 0 12558 12558 0 Total Offering Amount represents price of 200,000 Class A common shares at C$0.085 per share, converted at C$1:$0.7387. false 1 0 0 0 false Algernon Pharmaceuticals Inc. /s/ James Kinley James Kinley Chief Financial Officer 2024-04-09